Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study

No standard chemotherapy is available after disease progression or anaphylaxis during platinum chemotherapy among patients with recurrent cervical cancer. Here we report the efficacy and toxicities of metronomic chemotherapy consisting of 50 mg of oral cyclophosphamide (CPA) daily and intravenous 15...

Full description

Bibliographic Details
Main Authors: Roze Isono-Taniguchi, Mayako Goto, Yumi Takimoto, Tomoko Ueda, Yu Wakimoto, Kayo Inoue, Kensuke Hori, Kimihiko Ito, Hiroshi Tsubamoto
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Gynecologic Oncology Reports
Subjects:
Metronomic chemotherapy
Cyclophosphamide
Bevacizumab
Cervical cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578922000935

Internet

http://www.sciencedirect.com/science/article/pii/S2352578922000935

Similar Items